+

WO2005097224A1 - Empreinte revêtue de polymere - Google Patents

Empreinte revêtue de polymere Download PDF

Info

Publication number
WO2005097224A1
WO2005097224A1 PCT/JP2005/006063 JP2005006063W WO2005097224A1 WO 2005097224 A1 WO2005097224 A1 WO 2005097224A1 JP 2005006063 W JP2005006063 W JP 2005006063W WO 2005097224 A1 WO2005097224 A1 WO 2005097224A1
Authority
WO
WIPO (PCT)
Prior art keywords
stent
polymer
coating
metal
primer
Prior art date
Application number
PCT/JP2005/006063
Other languages
English (en)
Japanese (ja)
Inventor
Ikuo Omura
Shuzou Yamashita
Kouji Mori
Original Assignee
Japan Stent Technology Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Stent Technology Co., Ltd. filed Critical Japan Stent Technology Co., Ltd.
Publication of WO2005097224A1 publication Critical patent/WO2005097224A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
    • A61F2002/3006—Properties of materials and coating materials
    • A61F2002/30069—Properties of materials and coating materials elastomeric
    • A61F2002/3007—Coating or prosthesis-covering structure made of elastic material, e.g. of elastomer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2420/00—Materials or methods for coatings medical devices
    • A61L2420/08—Coatings comprising two or more layers

Definitions

  • the present invention relates to a polymer one-coated stent having a polymer film firmly adhered to the surface of a metal stent and exhibiting excellent durability in which the polymer film does not peel off in a biological environment. About.
  • a stent is an annular medical device that is placed at a site in a living body such as a blood vessel, a trachea, a bile duct, etc., where the stenosis is obstructed or obstructed in order to secure a necessary lumen region.
  • Tool. The stent is used to contract the tube diameter, insert it into the body by reducing it, expand it at a stenosis or the like, increase the tube diameter, and expand and hold the lumen.
  • percutaneous transluminal coronary angioplasty (1 ⁇ 10 1 & 5) (hereinafter referred to as?
  • Patent Document 1 JP-A-8-33718
  • an object of the present invention is to provide a polymer-coated stent having improved durability by suppressing deterioration of adhesion between a polymer film and a base metal in an in vivo environment.
  • Another object of the present invention is to provide a polymer-coated stent having both a drug-eluting property and a bonding durability of a polymer film to a metal.
  • the inventors of the present invention have conducted intensive studies to solve the above-mentioned problems. As a result, the surface of a metal stent was coated with a specific primer by force, and after being pressed, a polymer film was coated to form a polymer. The inventor has found that the coating adheres firmly to the metallic stent and that the adhesive durability in an in-vivo environment is significantly improved. The inventors have further studied and completed the present invention.
  • a specific primer is coated on the surface of a metal stent, and thereafter, a stent coated with a polymer film and a polymer film containing a therapeutic agent are further coated on the stent.
  • a stent coated with a polymer film and a polymer film containing a therapeutic agent are further coated on the stent.
  • the metal which is the material of the stent those having high corrosion resistance and high elasticity are preferable, and stainless steel, tantalum, nickel titanium alloy (including -tinol) and cobalt alloy (cobalt chromium) are preferable examples. Including a nickel alloy).
  • the ability to coat these stents with a specific primer on these metal-processed stents In order to maximize the effectiveness of the primer, it is necessary to clean the metal surface.
  • a method used industrially is preferably used. That is, water washing, steam washing, solvent washing, mechanical polishing, chemical polishing, plasma washing, and ultraviolet (UV) Z ozone washing.
  • the specific primer used in the present invention includes an organic compound having a plurality of acidic hydroxyl groups and at least one functional group in a molecule (hereinafter, referred to as an acidic hydroxyl group-containing compound). It is one to which additives described later such as a volatile organic solvent are added.
  • the acidic hydroxyl group of the acidic hydroxyl group-containing compound include hydroxyl groups of carboxylic acid, phosphoric acid monoester, phosphoric acid diester, phosphonic acid, phosphonic acid monoester, and phenol.
  • a polymerizable group such as a (meth) atalyloyl group and a vinyl group, an amino group Amide group, epoxy group, isocyanate group, acid chloride group, acid anhydride group, hydroxyl group, mercapto group, azide group, trialkoxysilyl group and the like.
  • the carbon number of the acidic hydroxyl group-containing compound in which a plurality of acidic hydroxyl groups and at least one functional group are bonded is preferably from 3 to 500, more preferably from 2 to 10,000.
  • the acidic hydroxyl groups chemisorb to the metal surface of the stent, while the functional groups result in chemical bond formation between the components of the primer or with Z and the polymer coating deposited on the primer.
  • a pramer containing an acidic hydroxyl group-containing compound having a plurality of acidic hydroxyl groups bonded to a carboxyl group or Z and a phosphorus atom strongly adheres to various metals, particularly base metals, and has high adhesion durability in a biological environment.
  • adhesion durability is high. Is significantly improved.
  • suitable acidic hydroxyl group-containing compounds include 4-methacryloyloxyschiltrimellitic acid, 11-methacryloyloxy-1,1-undecanedicarboxylic acid, arylphosphonic acid, and 10-methacryloyloxydecyl diamine.
  • polymerizable monomers such as hydrogen phosphate, 10-aminodecylphosphonic acid, 11-hydroxy-1,1,1-decanedicarboxylic acid, and glycidyl trimellitic acid.
  • additives such as monomers, prepolymers, polymers, coupling agents, cross-linking agents, volatile solvents, surfactants, and polymerization initiators are used as necessary. It is blended.
  • the amount of the acidic hydroxyl group-containing conjugate in the primer is 0.01 to: LOO weight%, preferably 0.1 to: LOO weight%.
  • the coating of the primer onto the metal stent is performed by a method such as dipping, spin coating, spraying and the like.
  • the thickness of the coated primer is preferably between 0.001 and 1 ⁇ m. Therefore, it is necessary to select the composition of the primer and the coating method so that the coating layer is uniform and thin. For example, after coating with a primer, the excess primer can be washed with a solvent and then flown to leave only the acidic hydroxyl group-containing compound chemically adsorbed on the metal surface. If the primer contains a solvent, drying is required.
  • the primer is polymerizable, it can be polymerized and cured by a method such as heating, UV irradiation, or electron beam irradiation.
  • the polymer to be coated on the primer layer is selected according to the purpose of the polymer film. If the polymer coating is expected to degrade and disappear over time when the stent is placed in a living body, a biodegradable polymer can be coated, but the polymer is stable in the living body and For ordinary applications that require no exposure of the stent metal surface due to degradation and degradation, a polymer with high biostability and biocompatibility (hereinafter referred to as biostable polymer) should be selected.
  • biostable polymer a polymer with high biostability and biocompatibility
  • the polymer suitable for the present invention is a biocompatible polymer having biostability, hydrophobicity and flexibility.
  • Specific examples of such polymers include fluorosilicone-based resin, silicone-based resin, polyester-based resin, polyamide-based resin, polyurethane-based resin, polyethylene, (meth) atalylate-based polymer, and poly (ethylene butyl). Alcohol), homo- or copolymers of 2-methacryloyloxydecyl phosphorylcholine, and (2-hydroxyethyl methacrylate) styrene block copolymer.
  • a method of forming a polymer film on the primer includes a method of diluting a polymer with a solvent and coating the surface of the stent, and then evaporating the solvent to form a film (method A); The method is roughly divided into two methods: coating the monomer surface on the stent surface, and then polymerizing or Z-curing after crosslinking and curing by crosslinking (method B). Method A is applied to the formation of a film of a linear polymer that can be dissolved in a solvent, for example, a polybutyl methacrylate or a poly (ethylene vinyl alcohol) copolymer.
  • Method B applies to prepolymers or Z and monomers in which the polymerization or Z and cross-linking reactions proceed in the Balta state. Specific examples thereof include prepolymers of epoxy resin, urethane resin, silicone resin, (meth) acrylate resin, and Z and monomers.
  • a solvent, a polymer, a filler, and a polymerization initiator are added as necessary. If a solvent is added, before polymerization or cross-linking In addition, it is necessary to volatilize and remove the solvent.
  • Polymerization Z cross-linking is performed by an intermolecular cross-linking reaction of prepolymers in epoxy resins, urethane resins, and silicone resins.
  • the polymerization is carried out by radical polymerization of monomers.
  • the polymerization reaction is started and progressed by activating means such as heating of the coating layer of the monomer, irradiation of visible light to UV, and irradiation of electron beam. Since the radical polymerization reaction is hindered by oxygen in the air, the polymerization is preferably performed in an atmosphere of an inert gas such as nitrogen or argon or in a vacuum.
  • the thickness of the polymer coating is usually 0.1 to 200 111, preferably 0.1 to 50 m, and the desired coating thickness can be achieved by repeating coating from 1 to: LOO times.
  • drug elution can be imparted to the polymer film as required.
  • a biodegradable or hydrophilic polymer film that adheres to the biostable polymer film is formed on the biostable polymer film, and the drug is incorporated in the film.
  • the biodegradable polymer include polycaprolactone, poly L-lactic acid, poly DL lactic acid, polyglycolide, polylactide, glycolide lactide copolymer, polyether, polyorthoester, polyiminocarbonate, aliphatic polycarbonate, Examples thereof include polyamide and polyphosphazene.
  • hydrophilic polymer examples include polyethylene oxide, sulfonidopolyethylene oxide, poly (2-hydroxyethyl methacrylate), polyacrylamide, polyvinylpyrrolidone, and polyvinyl alcohol. It is of course possible to apply these polymer coatings (hereinafter referred to as biodegradable or hydrophilic polymer coatings) directly on the underlying biostable polymer coating, but if the adhesion of both coatings is poor. In order to improve the adhesion, it is necessary to apply a surface treatment to the biostable polymer film prior to coating to activate the film.
  • Examples of the surface treatment include chemical treatment with an oxidizing agent or fluorine gas, surface graft polymerization, plasma discharge treatment, corona discharge treatment, UVZ ozone treatment, and electron beam irradiation.
  • the biodegradable polymer is dissolved in a volatile solvent to form a solution, which is coated on an untreated or surface-treated biostable polymer film surface, and the solvent is removed by means such as reduced pressure, air blowing, and heating.
  • Examples of the volatile solvent include tetrahydrofuran, methylene chloride, chloroform, acetonitrile, methyl ethyl ketone, methanol, dimethyl sulfoxide, N, N-dimethylformamide, water, and mixtures thereof. I can make it.
  • Drugs to be eluted are antiplatelet agents, anticoagulants, thrombolytic agents, antifibrin, antithrombin, immunosuppressants, antiproliferative agents, anti-inflammatory agents, pile cancer agents, antioxidants, anti-metabolites , Anti-mitotic agents, hyperplasia inhibitors, smooth muscle cell inhibitors, antibiotics, growth factors, growth factor inhibitors, cell adhesion inhibitors, cell adhesion promoters and healthy neointimal tissue formation promoters, etc. is there. Also, genes, plasmids, decoys, antisenses and the like having a therapeutic effect can be incorporated in the polymer film and eluted in the same manner as the above-mentioned drugs.
  • the simplest way to elute the drug from the biodegradable or hydrophilic polymer coating is to disperse the drug in the polymer at a molecular level to a micron size.
  • a solution or dispersion obtained by dissolving or dispersing a drug as fine particles (even microcapsules) in the polymer solution is coated on a biostable polymer film.
  • Coating is performed by a method such as dipping, spin coating, or spraying. By forcibly removing the solvent after coating, the polymer film containing the drug can be formed. Coating is repeated from 1 to as necessary: LOO times, and the coating thickness is controlled to 0.1 to 200 ⁇ m.
  • the rate of elution of a drug from a stent in a living body depends on the rate of degradation of a biodegradable or hydrophilic polymer and the rate of diffusion of a therapeutic agent within the polymer that has swollen by water. If the drug disperses too quickly in the polymer despite the slow rate of degradation of the polymer, and almost all of the drug elutes in a short period of time, the drug molecules will be adsorbed to the polymer and the diffusion will be delayed. It is necessary to modify the polymer, and the chemical modification performed for this purpose is specifically the introduction of a functional group such as a hydroxyl group, a carboxyl group, a sulfonic acid group, or an amino group. The interaction of the drug molecule functional groups with these functional groups slows the diffusion of the drug molecule and provides sustained release.
  • a functional group such as a hydroxyl group, a carboxyl group, a sulfonic acid group, or an amino group.
  • the polymer-coated stent of the present invention has a polymer coating having excellent adhesion and durability formed on the surface of the metal stent, which is a weak point of the conventional polymer-coated metal stent, that is, the coating that occurs after implantation in a living body. Peeling can be prevented. As a result, the reocclusion rate after placement of an intravascular stent is reduced, and the addition of drug elution prevents thrombus and intimal hyperplasia. And the reocclusion rate is further reduced.
  • FIG. 1 shows a stent according to an embodiment.
  • One embodiment capable of maximizing the effects of the present invention is as follows. That is, the surface of the metal stent to be coated with the polymer is washed with distilled water and then with a chlorine-based organic solvent such as trichloroethane to remove dirt, and then subjected to plasma cleaning to obtain a clean metal surface.
  • a chlorine-based organic solvent such as trichloroethane to remove dirt
  • plasma cleaning to obtain a clean metal surface.
  • a coating solution obtained by dissolving 1 to 20% by weight of polyalkyl methacrylate and an appropriate amount of an ultraviolet polymerization initiator in methyl methacrylate (MMA) is applied to the surface of the primer-treated stent, and MMA is placed in a nitrogen atmosphere. Removed at room temperature to form a polymer film. Then, irradiate UV for about 10 minutes to completely cure the coating. Furthermore, a polylactic acid Z methylene chloride solution (polymer concentration: 1 to 20% by weight) in which an appropriate amount of fine powder of a drug such as henolin is dispersed is applied, and the methylene chloride is evaporated under reduced pressure at room temperature to produce biodegradation. Generate a functional polymer film.
  • MMA methyl methacrylate
  • the polymer-coated stent manufactured by the above-described steps is capable of preventing the polymer coating from peeling off from the metal surface even when the stent is left in an in-vivo environment for a long period of time.
  • the sustained release of the drug clearly prevents restenosis of the lumen.
  • a force disclosed mainly in an intravascular stent as an example of the present invention is not limited to an intravascular stent.
  • the present invention is not limited to an intravascular stent, and is used for a lumen such as trachea, bile duct, and intestinal tract. Is also included.
  • FIG. 1 shows a stent 2 of an embodiment.
  • the core wire 4 of Co—Cr alloy, etc.
  • a primer layer 4 and a polymer layer 6 having a predetermined thickness are provided.
  • the primed stent was immersed in the polymer coating solution prepared for 5 seconds, immediately pulled up from the solution, and lightly drained. After that, MMA was volatilized by standing still in a nitrogen stream at 50 ° C for 30 minutes under light shielding.
  • the stent was placed in a sealed container made of quartz glass, the air in the container was replaced with nitrogen gas, and light from a metal halide lamp (200 W) was applied for 5 minutes at a short distance.
  • the above-described polymer coating operation was repeated three times. In the third time, after irradiation with light, the stent was allowed to stand in a closed container for 6 hours.
  • the state of the polymer film on the stent surface was observed with a stereoscopic microscope (magnification: X100), and it was confirmed that the film had no defects such as cracks or peeling. confirmed.
  • the stent was immersed in a pH 7.4 phosphate buffer solution at 37 ° C and stored for 4 months. After the storage was completed, the stent was dried and observed with a stereoscopic microscope (magnification: X100). As a result, no cracks or delamination defects of the coating were observed.
  • Example 1 a polymer coating was formed on the stent surface under the same conditions except that the primer treatment was omitted.
  • the stent was expanded with a balloon, and the state of the polymer coating on the stent surface was observed with a stereoscopic microscope (magnification: X100). As a result, defects in which the coating was partially peeled off from the base metal were observed.
  • the stent was immersed in a pH 7.4-phosphate buffer solution at 37 ° C and stored for 4 months. After the storage was completed, the stent was dried and observed with a stereoscopic microscope. As a result, many portions where the coating peeled off from the base metal were observed.
  • Example 2 On the surface of the stent on which a coating mainly composed of polybutyl methacrylate was formed according to the method of Example 1, a hydrophilic polymer coating containing sarpodalelate hydrochloride was laminated according to the method described below. 30 wt% of glycerol monomethacrylate Tari rate, 4 wt% of glycerol dimethacrylate Tatari rate, 20 weight 0/0 hydrochloric acid Sarupodarerato were formulated a photopolymerizable coating solution consisting of 1% by weight of TMDPO and 45 wt% MMA .
  • a stent having a coating of polybutyl methacrylate was immersed in the liquid for 5 seconds in an unexpanded state, and then pulled up from the liquid to drain off excess liquid.
  • the stain to which the coating solution was adhered was placed in a sealed container made of quartz glass, and the air in the container was replaced with nitrogen gas.
  • light from a metal halide lamp (200 W) was applied for 5 minutes at a short distance.
  • the above coating was repeated again.
  • the stent was allowed to stand in a closed container for 6 hours, taken out, and expanded by inserting a balloon into the stent.
  • the state of the polymer coating of the expanded stent was observed with a stereoscopic microscope (magnification: X100).
  • the stent was immersed in a pH 7.4-phosphate buffer at 37 ° C and stored for 4 months. After the storage was completed, the stent was dried and observed with a stereoscopic microscope, but no exposure of the base metal due to deterioration of the coating was observed.
  • a biodegradable polymer film containing sarpodalelate hydrochloride was laminated on the surface of the stent on which a film containing polybutyl methacrylate as a main component was formed according to the method of Example 1 according to the method described below. 6 percent by weight of poly L-lactic acid and 4 wt% of hydrochloric acid Sarupogu Rerato and 90 weight 0/0 of Kurohohorumuka ⁇ Ranaru coating solution was formulated. A stent having a polybutyl methacrylate film was immersed in the solution for 5 seconds in an unexpanded state, and then pulled up from the solution to drain off the excess solution. The port form was evaporated in a stream of nitrogen at 50 ° C.
  • the primed stent is immersed for 5 seconds in N, N-dimethylformamide (DMF) solution in which 4% by weight of polyester-type thermoplastic urethane (Bionate 80A) is dissolved, and immediately pulled out of the solution and lightly Drained.
  • DMF N, N-dimethylformamide
  • the stent was transferred to a closed vessel capable of reducing pressure, dried under reduced pressure at room temperature for 1 hour, then heated to 70 ° C. while maintaining reduced pressure, and heat-treated for 6 hours. After the heat treatment, the stent was taken out of the container, and a balloon was inserted into the stent and expanded.
  • the state of the polymer coating on the expanded stent surface was observed with a stereoscopic microscope (magnification: X100), and it was confirmed that the coating had no defects such as cracks or peeling.
  • the stent was immersed in 37 ° C pH 7.4-phosphate buffer and stored for 4 months. After the storage was completed, the stent was dried and observed with a stereoscopic microscope (magnification: X100). As a result, no cracks or peeling defects were found in the coating.
  • a prototype Co—Cr alloy stent (surface cleaned with a solvent) was completely immersed in a 0.5 wt% aqueous solution of arylphosphonic acid in an unexpanded state, and allowed to stand at room temperature for 1 hour. One hour later, the stent was removed from the aqueous solution and air-dried for 30 minutes to complete the primer treatment.
  • a silicone elastomer solution prepared by dispersing a two-part silicone elastomer (MED-2111) containing 89 g of hexane with 10 g of the main agent and a hardening agent lg was prepared, and the solution was hand-sprayed. The stent was sprayed uniformly.
  • the stent was then heat cured in an oven at 60 ° C. for 24 hours to form a polymer coating.
  • a balloon was inserted into the stent where the coating was completed, and the stent was expanded.
  • the state of the polymer coating on the expanded stent surface was observed with a stereoscopic microscope (magnification: X100), and it was confirmed that the coating had no defects such as cracks and peeling.
  • the stent was immersed in 37 ° C PH7.4-phosphate buffer and stored for 4 months. After 4 months, the stent was dried and observed with a stereoscopic microscope (magnification: X100). No peeling defects were observed.
  • Example 1 a polymer coating was formed on the stent surface under the same conditions except that ⁇ -methacryloxypropyltrimethoxysilane was used instead of 10-methacryloyloxydecyl dihydrogen phosphate.
  • the stent was expanded with a balloon, and the state of the polymer film on the stent surface was observed with a stereoscopic microscope (magnification: X100). As a result, defects in which the film partially exfoliated the base metal force were observed.
  • the stent was immersed in a pH 7.4-phosphate buffer at 37 ° C and stored for 4 months. After the storage was completed, the stent was dried and observed with a stereoscopic microscope. As a result, many portions where the coating was peeled off from the base metal were observed.
  • Example 1 a polymer film was formed on the stent surface under the same conditions except that methacrylic acid was used instead of 10-methacryloyloxydecyl dihydrogen phosphate.
  • the stent was expanded with a balloon, and the state of the polymer film on the stent surface was observed with a stereoscopic microscope (magnification: X100). As a result, a defect in which the film was partially peeled off from the base metal was observed.
  • the stent was immersed in a pH 7.4-phosphate buffer at 37 ° C and stored for 4 months. After the storage was completed, the stent was dried and observed with a stereoscopic microscope. As a result, a large number of portions where the coating was peeled off from the base metal were recognized.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Epidemiology (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Il est divulgué une empreinte revêtue de polymère dans laquelle une adhésion entre un revêtement polymère et un métal de base est amélioré. Après le prétraitement du métal de base avec un primeur spécifique ayant un effet de renforcement d'adhésion, notamment un primeur contenant un composé organique ayant une pluralité de groupes hydroxyles acides et au moins un groupe fonctionnel dans une molécule, un revêtement polymère flexible et hydrophobique est formé sur le métal de base.
PCT/JP2005/006063 2004-04-08 2005-03-30 Empreinte revêtue de polymere WO2005097224A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004-142917 2004-04-08
JP2004142917A JP2007236399A (ja) 2004-04-08 2004-04-08 ポリマー被覆型ステント

Publications (1)

Publication Number Publication Date
WO2005097224A1 true WO2005097224A1 (fr) 2005-10-20

Family

ID=35124854

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/006063 WO2005097224A1 (fr) 2004-04-08 2005-03-30 Empreinte revêtue de polymere

Country Status (2)

Country Link
JP (1) JP2007236399A (fr)
WO (1) WO2005097224A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007058190A1 (fr) * 2005-11-16 2007-05-24 Tokai University Educational System Composition de libération dosée de médicament et dispositif médical de libération de médicament
US8409272B2 (en) 2007-09-04 2013-04-02 Japan Stent Technology Co., Ltd. Sustained drug-releasing stent
US8591571B2 (en) 2009-03-02 2013-11-26 Japan Stent Technology Co., Ltd. Drug-eluting stent
CN110584849A (zh) * 2019-10-14 2019-12-20 江苏诺瑞思医疗器械有限公司 形状记忆合金覆膜带锚支架及其制造方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2870170C (fr) * 2012-09-12 2018-06-12 Boston Scientific Scimed, Inc. Revetement adhesif anti-migration pour endoprothese vasculaire
US9320592B2 (en) * 2013-03-15 2016-04-26 Covidien Lp Coated medical devices and methods of making and using same
US9545301B2 (en) 2013-03-15 2017-01-17 Covidien Lp Coated medical devices and methods of making and using same
US9668890B2 (en) 2013-11-22 2017-06-06 Covidien Lp Anti-thrombogenic medical devices and methods

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58173175A (ja) * 1982-04-05 1983-10-12 Kuraray Co Ltd 歯科用接着剤
JPS59138283A (ja) * 1983-01-28 1984-08-08 Kuraray Co Ltd 接着剤
JPH10231373A (ja) * 1997-01-03 1998-09-02 Huels Ag 基体の表面の生物活性被覆のための方法、および被覆した基体の応用
JP2000516827A (ja) * 1996-08-29 2000-12-19 メドトロニック・インコーポレーテッド 生体適合性医療用製品及び方法
JP2002172159A (ja) * 2000-12-07 2002-06-18 Terumo Corp 体内埋め込み医療器具
JP2003220146A (ja) * 2002-01-31 2003-08-05 Kawasumi Lab Inc ステント及びステントグラフト
JP2004089233A (ja) * 2002-08-29 2004-03-25 Kawasumi Lab Inc ステント

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58173175A (ja) * 1982-04-05 1983-10-12 Kuraray Co Ltd 歯科用接着剤
JPS59138283A (ja) * 1983-01-28 1984-08-08 Kuraray Co Ltd 接着剤
JP2000516827A (ja) * 1996-08-29 2000-12-19 メドトロニック・インコーポレーテッド 生体適合性医療用製品及び方法
JPH10231373A (ja) * 1997-01-03 1998-09-02 Huels Ag 基体の表面の生物活性被覆のための方法、および被覆した基体の応用
JP2002172159A (ja) * 2000-12-07 2002-06-18 Terumo Corp 体内埋め込み医療器具
JP2003220146A (ja) * 2002-01-31 2003-08-05 Kawasumi Lab Inc ステント及びステントグラフト
JP2004089233A (ja) * 2002-08-29 2004-03-25 Kawasumi Lab Inc ステント

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007058190A1 (fr) * 2005-11-16 2007-05-24 Tokai University Educational System Composition de libération dosée de médicament et dispositif médical de libération de médicament
JP5153340B2 (ja) * 2005-11-16 2013-02-27 学校法人東海大学 薬剤放出制御組成物および薬剤放出性医療器具
US8409272B2 (en) 2007-09-04 2013-04-02 Japan Stent Technology Co., Ltd. Sustained drug-releasing stent
US8641756B2 (en) 2007-09-04 2014-02-04 Japan Stent Technology Co., Ltd. Sustained drug-releasing stent
US8968392B2 (en) 2007-09-04 2015-03-03 Japan Stent Technology Co., Ltd. Method of inhibiting vascular intimal hyperplasia using stent
US9040111B2 (en) 2007-09-04 2015-05-26 Japan Stent Technology Co., Ltd. Method of making a stent
US8591571B2 (en) 2009-03-02 2013-11-26 Japan Stent Technology Co., Ltd. Drug-eluting stent
CN110584849A (zh) * 2019-10-14 2019-12-20 江苏诺瑞思医疗器械有限公司 形状记忆合金覆膜带锚支架及其制造方法

Also Published As

Publication number Publication date
JP2007236399A (ja) 2007-09-20

Similar Documents

Publication Publication Date Title
US10016533B2 (en) Plasma modified medical devices and methods
US8227016B2 (en) Laminated drug-polymer coated stent with dipped and cured layers
JP4493655B2 (ja) 薬物ポリマコーティングをステントに施す方法
EP2262547B1 (fr) Dispositifs de cathéter à ballonnet avec un polymère gonflable dans un solvant
US6908624B2 (en) Coating for implantable devices and a method of forming the same
JP4667393B2 (ja) フッ素化ポリマーコーティングを有する植込み型医療器具、およびその塗布方法
US20110093056A1 (en) Use of Plasma in Formation of Biodegradable Stent Coating
EP2442841B1 (fr) Dispositifs médicaux implantables et revêtements pour ceux-ci comprenant des copolymères séquencés de poly(éthylène glycol) et d'un poly(lactide-glycolide)
JP2005537097A (ja) デリバリーシステムのための保持コーティング
JP2009213928A (ja) 薬剤を放出するステントコーティング及び方法
JP2010533563A (ja) 吸着抑制表面を有する内部人工器官
JP2011517969A (ja) 機械的安定性が改善した埋め込み型医療デバイスコーティング
US20020065551A1 (en) Method for immobilizing poly(HEMA) on stents
JP2020520262A (ja) 医療機器
WO2005097224A1 (fr) Empreinte revêtue de polymere
US8114153B2 (en) Endoprostheses
US20070118211A1 (en) Method for preparing drug eluting medical devices and devices obtained therefrom
WO2005110507A1 (fr) Fil de guidage
EP4382144A1 (fr) Dispositif médical à élution de médicament et sa méthode de production
MXPA06004571A (en) Method for preparing drug eluting medical devices and devices obtained therefrom

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载